642 related articles for article (PubMed ID: 23924152)
1. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
2. The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy.
Campbell J; Reid J; Ordon M; Welk B
Urology; 2019 Aug; 130():126-131. PubMed ID: 31129193
[TBL] [Abstract][Full Text] [Related]
3. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
4. Impact of medical therapy on transurethral resection of the prostate: two decades of change.
Izard J; Nickel JC
BJU Int; 2011 Jul; 108(1):89-93. PubMed ID: 20883490
[TBL] [Abstract][Full Text] [Related]
5. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
[TBL] [Abstract][Full Text] [Related]
7. The changing practice of transurethral resection of the prostate.
Young MJ; Elmussareh M; Morrison T; Wilson JR
Ann R Coll Surg Engl; 2018 Apr; 100(4):326-329. PubMed ID: 29543050
[TBL] [Abstract][Full Text] [Related]
8. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
9. Treatment of benign prostatic hyperplasia.
Pinheiro LC; Martins Pisco J
Tech Vasc Interv Radiol; 2012 Dec; 15(4):256-60. PubMed ID: 23244720
[TBL] [Abstract][Full Text] [Related]
10. Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
Blanchard K; Hananel A; Rutchik S; Sullivan J
South Med J; 2000 Dec; 93(12):1192-6. PubMed ID: 11142455
[TBL] [Abstract][Full Text] [Related]
11. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
12. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes.
Mayer EK; Kroeze SG; Chopra S; Bottle A; Patel A
BJU Int; 2012 Dec; 110(11):1595-601. PubMed ID: 22540956
[TBL] [Abstract][Full Text] [Related]
13. Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.
Strope SA; Vetter J; Elliott S; Andriole GL; Olsen MA
Urology; 2015 Dec; 86(6):1115-22. PubMed ID: 26375848
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with continuing medical therapy after transurethral resection of prostate.
Han HH; Ko WJ; Yoo TK; Oh TH; Kim DY; Kwon DD; Byun SS; Kim SI; Jung TY
Urology; 2014 Sep; 84(3):675-80. PubMed ID: 25059592
[TBL] [Abstract][Full Text] [Related]
16. Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy.
Pham H; Sharma P
Can J Urol; 2018 Apr; 25(2):9228-9237. PubMed ID: 29679999
[TBL] [Abstract][Full Text] [Related]
17. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
[TBL] [Abstract][Full Text] [Related]
18. Transurethral resection of the prostate in kidney transplant recipients: urological and renal functional outcomes at long-term follow-up.
Volpe A; Billia M; Quaglia M; Vidali M; Marchioro G; Ceratti G; Sogni F; De Lorenzis E; De Angelis P; Airoldi A; Stratta P; Terrone C
BJU Int; 2013 Aug; 112(3):386-93. PubMed ID: 23496755
[TBL] [Abstract][Full Text] [Related]
19. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
20. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
